Serum soluble TREM2 is an independent biomarker associated with coronary heart disease

• Published in: Clinica chimica acta 2023-08, Vol.548, p.117499-117499, Article 117499
• Main Authors: Liu, Wenwu, Weng, Shuwei, Liu, Huixing, Cao, Chenghui, Wang, Shuai, Wu, Sha, He, Jia, Yang, Yang, Hu, Die, Luo, Yonghong, Peng, Daoquan
• Format: Article
• Language: English
• Subjects: Atherosclerosis; Coronary heart disease; Inflammation; Lipid metabolism; sTREM2; Triggering Receptor Expressed in Myeloid Cells 2
• ISSN: 0009-8981; 1873-3492
• DOI: 10.1016/j.cca.2023.117499

•Patients with coronary heart disease have higher serum sTREM2 levels.•In CHD patients, sTREM2 levels were associated with levels of triglyceride, HDL-C, apoB, and smoking status.•sTREM2 was associated independently with coronary heart disease.•sTREM2 showed better diagnostic value than traditional biomarkers, like Apolipoprotein B. Triggering receptor expressed on myeloid cells 2 (TREM2) is a unique receptor expressed by macrophages in atherosclerotic plaque and is involved in the progression of atherosclerosis. Whether serum soluble TREM2 (sTREM2) levels has a relationship with coronary heart disease (CHD) remains unclear. The cross-sectional study included 86 patients with CHD and 86 controls matched with age and sex. Demographic information, medication history, and laboratory data were collected. sTREM2 concentrations were detected by enzyme-linked immunosorbent assay. We compared the sTREM2 levels in two groups and constructed stepwise linear regression analysis for factors related to the sTREM2 level in patients with CHD; we further used the logistic regression model to evaluate the relationship between sTREM2 and CHD. The diagnostic value of sTREM2 and other biomarkers in CHD was evaluated by the receiver operating characteristic curve (ROC). The serum level of sTREM2 in CHD patients is higher than that in controls. In CHD patients, the stepwise linear regression analysis found that sTREM2 levels were correlated with triglyceride (TG), high-density lipoprotein cholesterols (HDL-C), apolipoprotein B (ApoB) and smoking status. Logistic regression models showed that sTREM2 was associated independently with CHD after adjusted confounders. The ROC curve showed a sensitivity of 59.3% and specificity of 81.4% with an area under the curve of 0.781 (95% CI: 0.711–0.852) for the diagnosis of CHD with serum sTREM2 at a cut-off value of > 1104.894 pg/ml, indicating a higher diagnostic value than high sensitivity C reaction protein (hs-CRP) and apolipoprotein B (ApoB). In this study, we provide evidence that sTREM2 levels are elevated in CHD patients and are associated with various cardiovascular risk factors. Additionally, sTREM2 demonstrates better diagnostic performance compared to traditional indicators in identifying CHD. These findings suggest that sTREM2 may serve as a potential biomarker for coronary heart disease.